Last reviewed · How we verify
AK112 with SCRT
AK112 with SCRT is a Small molecule Small molecule drug developed by fan li. It is currently in Phase 2 development for Unknown.
AK112 with SCRT is a small molecule that targets the molecular target to exert its therapeutic effect.
AK112, also known as Ivonescimab, is an antibody used in the treatment of rectal cancer. It is being studied in a clinical trial, STAR, as a follow-up treatment after short-course radiotherapy for mid-low rectal cancer.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AK112 with SCRT |
|---|---|
| Sponsor | fan li |
| Drug class | Small molecule |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Unknown |
| Phase | Phase 2 |
Mechanism of action
AK112 with SCRT works by binding to the molecular target, which leads to a cascade of downstream effects that ultimately result in the desired therapeutic outcome.
Approved indications
- Unknown
Common side effects
- Unknown
Key clinical trials
- SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer (PHASE2)
- Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer (PHASE2)
- Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer (PHASE2)
- Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK112 with SCRT CI brief — competitive landscape report
- AK112 with SCRT updates RSS · CI watch RSS
- fan li portfolio CI
Frequently asked questions about AK112 with SCRT
What is AK112 with SCRT?
How does AK112 with SCRT work?
What is AK112 with SCRT used for?
Who makes AK112 with SCRT?
What drug class is AK112 with SCRT in?
What development phase is AK112 with SCRT in?
What are the side effects of AK112 with SCRT?
What does AK112 with SCRT target?
Related
- Drug class: All Small molecule drugs
- Target: All drugs targeting Unknown
- Manufacturer: fan li — full pipeline
- Therapeutic area: All drugs in Unknown
- Indication: Drugs for Unknown
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing